Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 ± empagliflozin in compensated cirrhosis with CSPH
CTR20222573Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avenciguat in Portal Hypertension (PH), Cirrhosis, hepatitis C virus infection, hepatitis B (HBV), metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Boehringer Ingelheim. Started Oct 2022; status: terminated.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)Cirrhosishepatitis C virus infectionhepatitis B (HBV)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20222573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222573.